Invesaro

Stocks Comparison

biote vs Usana Health Sciences: revenue, profit, margins and growth compared

biote brought in $192.2M of revenue in fiscal 2025, Usana Health Sciences $925.3M in fiscal 2025. Revenue changed by -2.5% at biote and +8.3% at Usana Health Sciences on the year before, so Usana Health Sciences grew faster. biote kept 14.1% of its revenue as net profit, Usana Health Sciences 1.2%. Free cash flow was $30.2M at biote and $8.5M at Usana Health Sciences.

Side by side, latest fiscal year

BTMDUSNA
Fiscal year endedFY2025 (December 31, 2025)FY2025 (January 3, 2026)
Revenue$192.2M$925.3M
Revenue growth-2.5%+8.3%
Net income$27M$10.8M
Net margin14.1%1.2%
Free cash flow$30.2M$8.5M
Free cash flow margin15.7%0.9%
Earnings per share (diluted)$0.74$0.58
Cash$24.1M$158.4M
Debt$103.1Mn/a
Price to earnings1.625.0
Market value$43.8M$267.9M
Dividend yieldn/an/a
Rank by revenue in sector#256 of 523 · Health care#150 of 523 · Health care

Over the years

Revenue
BTMD FY2021: $139.4MBTMD FY2022: $165MBTMD FY2023: $185.4MBTMD FY2024: $197.2MBTMD FY2025: $192.2MUSNA FY2018: $1.2BUSNA FY2019: $1.1BUSNA FY2020: $1.1BUSNA FY2022: $1.2BUSNA FY2022: $998.6MUSNA FY2023: $921MUSNA FY2023: $854.5MUSNA FY2025: $925.3MFY18FY19FY20FY21FY22FY23FY24FY25
BTMD $192.2MUSNA $925.3M
Net income
BTMD FY2021: $11.1MBTMD FY2022: -$969KBTMD FY2023: $3.3MBTMD FY2024: $3.2MBTMD FY2025: $27MUSNA FY2018: $126.2MUSNA FY2019: $100.5MUSNA FY2020: $124.7MUSNA FY2022: $116.5MUSNA FY2022: $69.4MUSNA FY2023: $63.8MUSNA FY2023: $42MUSNA FY2025: $10.8MFY18FY19FY20FY21FY22FY23FY24FY25
BTMD $27MUSNA $10.8M
Net margin
BTMD FY2021: 8.0%BTMD FY2022: -0.6%BTMD FY2023: 1.8%BTMD FY2024: 1.6%BTMD FY2025: 14.1%USNA FY2018: 10.6%USNA FY2019: 9.5%USNA FY2020: 11.0%USNA FY2022: 9.8%USNA FY2022: 6.9%USNA FY2023: 6.9%USNA FY2023: 4.9%USNA FY2025: 1.2%FY18FY19FY20FY21FY22FY23FY24FY25
BTMD 14.1%USNA 1.2%
Revenue growth
BTMD FY2022: +18.3%BTMD FY2023: +12.4%BTMD FY2024: +6.4%BTMD FY2025: -2.5%USNA FY2019: -10.8%USNA FY2020: +7.0%USNA FY2022: +4.6%USNA FY2022: -15.8%USNA FY2023: -7.8%USNA FY2023: -7.2%USNA FY2025: +8.3%FY19FY20FY22FY23FY24FY25
BTMD -2.5%USNA +8.3%
Free cash flow
BTMD FY2021: $32.3MBTMD FY2022: -$9.5MBTMD FY2023: $26.5MBTMD FY2024: $38.8MBTMD FY2025: $30.2MUSNA FY2018: $140.7MUSNA FY2019: $110.2MUSNA FY2020: $145.3MUSNA FY2022: $108.5MUSNA FY2022: $93.5MUSNA FY2023: $56.1MUSNA FY2023: $50.9MUSNA FY2025: $8.5MFY18FY19FY20FY21FY22FY23FY24FY25
BTMD $30.2MUSNA $8.5M

Fiscal years as each company reports them; the two may end in different months.

Questions about biote and Usana Health Sciences

Which is bigger by revenue, biote or Usana Health Sciences?

Usana Health Sciences is bigger by revenue: $925.3M in fiscal 2025, against $192.2M for biote in fiscal 2025.

Which keeps more of its revenue as profit, biote or Usana Health Sciences?

biote had a net margin of 14.1% in fiscal 2025; Usana Health Sciences had 1.2% in fiscal 2025.

Which grew revenue faster, biote or Usana Health Sciences?

In their latest fiscal years revenue changed by -2.5% at biote and +8.3% at Usana Health Sciences.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies